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life by reducing symptoms and frequency of ex‑
acerbations and increasing effort tolerability. On 
the one hand, this justifies the adoption of a se‑
verity grading system based on clinical features, 
but exclusion of functional parameters does not 
allow a precise patient’s phenotyping. Converse‑
ly, it is a matter of fact that, although lung func‑
tion measures show gradual progression towards 
an emphysema pattern in GOLD stage 3 and 4,9 
it is well known that bronchitis and emphysema 
can occur independently of the FEV1 value and 
disease features. In the era of personalized med‑
icine, it is clear that COPD cannot be managed 
with a sole therapeutic approach any longer, while 
focusing on the most appropriate treatment in 
any selected patient is increasingly deemed as 
a critical strategy.10 In accordance with Safka et 
al,11 a change from GOLD 2011 to 2017 criteria 
leads to a consistent shift of patients from high‑
er (C and D) to lower (A and B) risk categories. 
This redistribution impairs in ‑between function‑
al and clinical differences and might jeopardize 
the predictability of important patient ‑centered 
outcomes, such as mortality.12 Obviously, this has 
economic implications. 
Since healthcare system sustainability of chron‑
ic disorders, such as COPD, needs a well ‑defined 
management plan, the analysis performed by 
Brożek et al13 provides relevant information. In 
a population sample of 2597 patients with COPD 
treated by a random population of Polish gener‑
al practitioners, the authors simulated the im‑
pact of GOLD guideline updates on direct costs.
Three key messages could be drawn from 
this research. First of all, independently of 
Chronic obstructive pulmonary disease (COPD) 
is a complex and heterogenous disorder, charac‑
terized by high morbidity and mortality rates.1 It 
represents a major social and economic burden for 
healthcare systems worldwide.2 The reduction of 
risk factors, treatment of comorbidities, and pre‑
vention of acute exacerbations are key elements 
of proper disease management.
Forced expiratory volume in 1 second (FEV1) 
is a marker of airflow obstruction. Due to its re‑
liability and reproducibility, it has been frequent‑
ly adopted as outcome in clinical research and for 
defining disease severity. However, observational 
studies, such as the ECLIPSE study (Evaluation of 
COPD Longitudinally to Identify Predictive Sur‑
rogate Endpoints), have clearly shown that FEV1 
poorly correlates with the patient’s global perfor‑
mance and health ‑related variables, such as co‑
morbidities, symptoms, quality of life,3,4 exacer‑
bations,5 hospitalization, and mortality rates.6,7
To address this complexity, multiple multi‑
dimensional grading systems have been devel‑
oped. The Global Initiative for Chronic Obstruc‑
tive Lung Disease (GOLD), moved from a FEV1‑
‑based severity grading (2007) to the ABCD clas‑
sification, which stratifies patients according to 
symptoms and exacerbation history (2011). In 
the 2017 update of GOLD recommendations, spi‑
rometry was removed from the risk stratification 
and treatment algorithm, leaving FEV1 alone for 
diagnostic purposes.8
Until now, no pharmacological treatment has 
proved to be significantly effective in modifying 
the progressive course of the disease, but available 
drugs are able to improve the patient’s quality of 
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the classification of severity adopted, the more 
severe forms of COPD are the most expensive. In 
contrast to asthma, we are not able yet to achieve 
the total control of COPD in its different stages. 
Worsening of lung function, dyspnea burden, and 
the rate of exacerbation lead to a step ‑up approach 
of pharmacotherapy. Two points need to be fur‑
ther explored: the ability of early combined long‑
‑term treatment with fixed doses of bronchodila‑
tors to reduce lung function decline, and the effi‑
cacy of target treatment (ie, biological drugs) in 
changing the natural history of the disease. We 
must also pay more attention to define the sever‑
ity of the disease and the needs of our patients, 
since the change in classification parameters leads 
to switching of patients from one stage to anoth‑
er. In particular, GOLD 2017 considerably reduced 
the number of patients in C and D groups. Final‑
ly, a significant reduction of direct costs was ob‑
served at each update of GOLD guidelines.
As mentioned by the authors, the cost of phar‑
macotherapy represents only part of the total 
cost of COPD, but a proper therapeutic strategy 
can influence the indirect cost (ie, hospitalization 
due to disease exacerbations). In recent trials ex‑
ploring the efficacy of single ‑inhaler triple ther‑
apy, patients treated in the context of a clinical 
trial where adherence to treatment is monitored 
have shown about 50% reduction of disease exac‑
erbation during the follow ‑up in comparison with 
the previous year.14,15 Furthermore, these trials 
were consistent in confirming that different com‑
binations of drugs lead to different clinical effects 
in different patients. For example, IMPACT (In‑
forming the Pathway of COPD Treatment) data15 
showed that the greater the rate of blood eosino‑
phils, the greater the effect of inhaled corticoste‑
roids on reducing the exacerbation. On the oth‑
er hand, the benefits of inhaled corticosteroids 
in smokers were limited.
Fulfilling patient’s needs, expressed as classi‑
fication of disease severity and drugs’ efficacy in 
specific groups of patients, is a matter of discus‑
sion. A recent release of the GOLD document8 has 
further fueled this debate. The updated recom‑
mendation suggests considering the grade of ob‑
struction (1 to 4) and the impact of symptoms and 
exacerbation risk (A, B, C, D) for defining the dis‑
ease severity. This system should facilitate a bet‑
ter understanding of the impact of COPD at an 
individual level and provision of a tailored treat‑
ment. Concerning this point, there is a model for 
pharmacological management of COPD according 
to the individualized evaluation of symptoms and 
exacerbation risk following the ABCD assessment, 
although the lack of high ‑quality evidence sup‑
porting initial pharmacological treatment strat‑
egies in newly diagnosed COPD patients is ev‑
ident. The document provides a separate algo‑
rithm for the follow ‑up treatment, where the es‑
calation and de ‑escalation of drugs are still based 
on symptoms and exacerbations, but the recom‑
mendations do not depend on GOLD group clas‑
sification at diagnosis.
